![Dewey McLin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dewey McLin is currently the Vice President & Head-Medical Affairs at Longboard Pharmaceuticals, Inc. Previously, he held the position of Senior Director-Medical Affairs at Greenwich Biosciences, Inc. In 2021, he briefly served as the Vice President-Medical Affairs at Sesen Bio, Inc. Dr. McLin completed his undergraduate degree at Indiana University and obtained a doctorate from the University of California, Irvine.
| Unternehmen | Position | Beginn |
|---|---|---|
| LONGBOARD PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Unternehmen | Position | Ende |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2021 |
Greenwich Biosciences, Inc.
 Greenwich Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets cannabinoid prescription medicines through online | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
Greenwich Biosciences, Inc.
Greenwich Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets cannabinoid prescription medicines through online | Health Technology |
Longboard Pharmaceuticals, Inc.
 Longboard Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for neurological diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
